Mesenchymal stem cell-derived molecules reverse fulminant hepatic failure
Biju Parekkadan, Daan van Poll, Kazuhiro Suganuma, Edward A Carter, François Berthiaume, Arno W Tilles, Martin L Yarmush, Biju Parekkadan, Daan van Poll, Kazuhiro Suganuma, Edward A Carter, François Berthiaume, Arno W Tilles, Martin L Yarmush
Abstract
Modulation of the immune system may be a viable alternative in the treatment of fulminant hepatic failure (FHF) and can potentially eliminate the need for donor hepatocytes for cellular therapies. Multipotent bone marrow-derived mesenchymal stem cells (MSCs) have been shown to inhibit the function of various immune cells by undefined paracrine mediators in vitro. Yet, the therapeutic potential of MSC-derived molecules has not been tested in immunological conditions in vivo. Herein, we report that the administration of MSC-derived molecules in two clinically relevant forms-intravenous bolus of conditioned medium (MSC-CM) or extracorporeal perfusion with a bioreactor containing MSCs (MSC-EB)-can provide a significant survival benefit in rats undergoing FHF. We observed a cell mass-dependent reduction in mortality that was abolished at high cell numbers indicating a therapeutic window. Histopathological analysis of liver tissue after MSC-CM treatment showed dramatic reduction of panlobular leukocytic infiltrates, hepatocellular death and bile duct duplication. Furthermore, we demonstrate using computed tomography of adoptively transferred leukocytes that MSC-CM functionally diverts immune cells from the injured organ indicating that altered leukocyte migration by MSC-CM therapy may account for the absence of immune cells in liver tissue. Preliminary analysis of the MSC secretome using a protein array screen revealed a large fraction of chemotactic cytokines, or chemokines. When MSC-CM was fractionated based on heparin binding affinity, a known ligand for all chemokines, only the heparin-bound eluent reversed FHF indicating that the active components of MSC-CM reside in this fraction. These data provide the first experimental evidence of the medicinal use of MSC-derived molecules in the treatment of an inflammatory condition and support the role of chemokines and altered leukocyte migration as a novel therapeutic modality for FHF.
Conflict of interest statement
Competing Interests: The authors have declared that no competing interests exist.
Figures
References
- Strain AJ, Neuberger JM. A bioartificial liver–state of the art. Science. 2002;295:1005–1009.
- Shinoda M, Tilles AW, Kobayashi N, Wakabayashi G, Takayanagi A, et al. A bioartificial liver device secreting interleukin-1 receptor antagonist for the treatment of hepatic failure in rats. J Surg Res. 2007;137:130–140.
- Shinoda M, Tilles AW, Wakabayashi G, Takayanagi A, Harada H, et al. Treatment of fulminant hepatic failure in rats using a bioartificial liver device containing porcine hepatocytes producing interleukin-1 receptor antagonist. Tissue Eng. 2006;12:1313–1323.
- Dazzi F, Ramasamy R, Glennie S, Jones SP, Roberts I. The role of mesenchymal stem cells in haemopoiesis. Blood Rev. 2006;20:161–171.
- Liechty KW, MacKenzie TC, Shaaban AF, Radu A, Moseley AM, et al. Human mesenchymal stem cells engraft and demonstrate site-specific differentiation after in utero transplantation in sheep. Nat Med. 2000;6:1282–1286.
- Le Blanc K, Rasmusson I, Sundberg B, Gotherstrom C, Hassan M, et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet. 2004;363:1439–1441.
- Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood. 2005;105:1815–1822.
- Zhang Y, Adachi Y, Suzuki Y, Minamino K, Iwasaki M, et al. Simultaneous injection of bone marrow cells and stromal cells into bone marrow accelerates hematopoiesis in vivo. Stem Cells. 2004;22:1256–1262.
- Meisel R, Zibert A, Laryea M, Gobel U, Daubener W, et al. Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood. 2004;103:4619–4621.
- Beyth S, Borovsky Z, Mevorach D, Liebergall M, Gazit Z, et al. Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T-cell unresponsiveness. Blood. 2005;105:2214–2219.
- Maitra B, Szekely E, Gjini K, Laughlin MJ, Dennis J, et al. Human mesenchymal stem cells support unrelated donor hematopoietic stem cells and suppress T-cell activation. Bone Marrow Transplant. 2004;33:597–604.
- Gnecchi M, He H, Liang OD, Melo LG, Morello F, et al. Paracrine action accounts for marked protection of ischemic heart by Akt-modified mesenchymal stem cells. Nat Med. 2005;11:367–368.
- Gnecchi M, He H, Noiseux N, Liang OD, Zhang L, et al. Evidence supporting paracrine hypothesis for Akt-modified mesenchymal stem cell-mediated cardiac protection and functional improvement. Faseb J. 2006;20:661–669.
- Shito M, Balis UJ, Tompkins RG, Yarmush ML, Toner M. A fulminant hepatic failure model in the rat: involvement of interleukin-1beta and tumor necrosis factor-alpha. Dig Dis Sci. 2001;46:1700–1708.
- Parekkadan B, van Poll D, Megeed Z, Tilles AW, Berthiaume F, et al. Immunomodulation of Activated Hepatic Stellate Cells by Mesenchymal Stem Cells. Biochem Biophys Res Commun. 2007 in press.
Source: PubMed